Benjamin J. Huang, MD
Assistant Professor of Pediatrics, UCSF; Attending Pediatric Hematologist/Oncologist, UCSF
I am a physician-scientist whose research program focuses on mouse cancer modeling, molecular therapeutics, functional genomics, and biomarker discovery in hematologic cancers. My recent data indicate that targeting downstream Ras effector pathways and bromodomain and extraterminal (BET) proteins is highly synergistic in vivo and represents a novel approach for the treatment of pediatric acute myeloid leukemia (AML). Additional contributions to science include collaborations that have involved RAS/NF1-driven cancers and the implementation of computational pipelines for analyzing integrated (epi)genomic preclinical and clinical data. These collaborations include recent projects that incorporate primary samples from patients enrolled on North American Children's Oncology Group clinical trials, as well as early phase clinical trials. My overall goal is to develop new therapeutic strategies in AML to inform biology-driven, genetically stratified trials of innovative drug combinations.
University of California, Berkeley, BS, 06/2005, Electrical Engineering and Computer Sciences
University of California, San Francisco, MD, 06/2010, Medicine
University of California, San Francisco, Residency, 06/2013, Pediatrics
University of California, San Francisco, Fellowship, 06/2016, Pediatric Hematology/Oncology
Le Q, Hadland B, Smith JL, Leonti A, Huang B, Ries R, Hylkema TA, Castro S, Tang TT, McKay CN, Perkins L, Pardo L, Sarthy J, Beckman AK, Williams R, Idemmili R, Furlan S, Ishida T, Call L, Srivastava S, Loeb AM, Milano F, Imren S, Morris SM, Pakiam F, Olson JM, Loken MR, Eidenschink Brodersen L, Riddell SR, Tarlock K, Bernstein ID, Loeb KR, Meshinchi S. CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target. J Clin Invest. 2022 Sep 22:e157101. doi: 10.1172/JCI157101.
Huang B, Smith JL, Farrar JE, Wang YC, Umeda M, Ries RE, Leonti AR, Crowgey E, Furlan SN, Tarlock K, Armendariz M, Liu Y, Shaw TI, Wei L, Gerbing R, Cooper TM, Gamis AS, Aplenc R, Kolb EA, Rubnitz J, Ma J, Klco JM, Ma X, Alonzo TA, Triche T, Meshinchi S. Integrated stem cell signature and cytomolecular risk determination in pedaitric acute myeloid leukemia. Nat Commun. 2022 Sep 19;13(1):5487. doi: 10.1038/s41467-022-33244-6.
Meyer LK, Delgado-Martin C, Sharp PP, Huang B, McMinn D, Vincent TL, Ryan T, Horton TM, Wood BL, Teachey DT, Taunton J, Kirk CJ, Hermiston ML. Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid reistance in T-cell acute lymphoblastic leukemia. Br J Haematol. 2022 Apr 17. doi: 10.1111/bjh.18181.
Umeda M, Ma J, Huang B, Hagiwara K, Westover T, Abdelhamed S, Barajas JM, Thomas ME, Walsh MP, Song G, Miller J, Hiltenbrand R, Liu Y, Chen X, Foy X, Iacobucci I, Kleist AB, Ries RE, Wu H, Rusch M, Alonzo TA, Maciaszek JL, Inaba H, Wu G, Valentine V, Valentine M, Liu YC, Mullighan CG, Pounds S, Babu MM, Zhang J, Rubnitz JE, Meshinchi S, Ma X, Klco JM. Integrated genomic analysis identifies UBTF tandem duplications as a recurrent lesion in pediatric acute myeloid leukemia. Blood Cancer Discov. 2022 Feb 16. doi: 10.1158/2643-3230.BCD-21-0160.
Huang B, Smith JL, Wang YC, Taghizadeh K, Leonti AR, Ries RE, Liu Y, Kolekar P, Tarlock K, Gerbing R, Crowgey EL, Furlan SN, Shaw TI, Hagiwara K, Wei L, Cooper TM, Gamis AS, Aplenc R, Kolb EA, Farrar JE, Triche T, Alonzo TA, Ma X, Meshinchi S. CBFB-MYH11 Fusion Transcripts Distinguish Acute Myeloid Leukemias with Distinct Molecular Landscapes and Outcomes. Blood Adv. 2021 Sep 21; bloodadvances.2021004965.